LANSING, Mich. — On Thursday, Michigan Attorney General Dana Nessel announced that Michigan will receive more than $4 million in a settlement agreement involving Indivior PLC and Indivior Inc. (Indivior).
The settlement covers six federal lawsuits and involves Indivior’s product Suboxone, a buprenorphine drug that was approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment.
Allegations detailed in lawsuits assert that, from 2010 through 2015, Indivior:
- promoted the sale and use of the drug to physicians who were writing prescriptions without having a medical purpose;
- knowingly promoted Suboxone Sublingual Film based on false and misleading claims that it was less subject to diversion and abuse than other buprenorphine products and less susceptible to accidental pediatric exposure than Suboxone Sublingual Tablets; and
- improperly controlled pricing of Suboxone, including pricing to state Medicaid programs, by submitting a petition to the Food and Drug Administration (FDA) on September 25, 2012, fraudulently claiming that Suboxone Tablet had been discontinued “due to safety concerns” and taking other steps to fraudulently delay the entry of generic competition for various forms of Suboxone.
Indivior will pay a total of $300 million to resolve these civil fraud allegations, which impacted Medicaid and other government programs.
►Make it easy to keep up to date with more stories like this. Download the 13 ON YOUR SIDE app now.